Dermata Therapeutics, Inc. (DRMA) stock

DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30

$0.62−0.04 (-6.01%)

Close on Nov 13, 2026Market cap $2.50MP/E –Yield –

Dermata Therapeutics statistics

53 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Mar 25, 2027 (estimated, after the close)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $2.50M; $272.32M
Enterprise Value: -$2.32M; $146.23M
PB Ratio: 0.64; 2.00
P/TBV Ratio: 0.64; 2.22

Share statisticsIndustry

Shares Outstanding: 4M; 58M
Shares Change (QoQ): 22.6%; 0.50%
Float: 3M; 49M
Shares Held by Insiders: 33.7%; 11.7%
Shares Held by Institutions: 3.05%; 56.4%

Short sellingIndustry

Short Interest: 84,233; –
Short Interest Change: 9.00%; -0.80%
Short % of Float: 3.16%; 9.01%
Short % of Shares Outstanding: 2.09%; 6.30%
Days to Cover: 1.00; 5.15

Stock price statisticsIndustry

52-Week High: $4.66; –
52-Week Low: $0.57; –
20-Day Moving Average: $0.78; –
50-Day Moving Average: $0.97; –
200-Day Moving Average: $1.23; –
Average True Range (14): $0.10; –
Price Change (1 Week): -18.7%; -1.15%
Price Change (1 Month): -31.7%; -4.87%
Price Change (3 Months): -57.5%; -21.0%
Price Change (6 Months): -47.8%; -20.6%
Price Change (YTD): -73.2%; -23.6%
Price Change (1 Year): -80.1%; -22.4%
Price Change (3 Years): -99.4%; -29.5%
Price Change (5 Years): -100.0%; -77.9%
Average Volume (10 Days): 87,115; –
Average Volume (20 Days): 148,208; –
Average Volume (90 Days): 2M; –
Relative Volume: 0.07; 0.70
Relative Strength Index (14): 33.3; 43.4
Volatility (1 Year): 131.9%; 80.1%
Beta (5 Years): 1.28; 1.07

Returns on capitalIndustry

Return on Equity (ROE): -241.5%; -49.9%
Return on Assets (ROA): -162.3%; -40.6%

EfficiencyIndustry

Profits Per Employee: -$1.06M; -$689.41K
Employee Count: 9; 74
WACC: 11.5%; 10.2%

Income statement (TTM)Industry

Operating Income: -$9.70M; -$21.37M
Net Income: -$9.50M; -$22.35M
EBITDA: -$9.70M; -$17.21M
EPS (Diluted): -$3.42; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $4.82M; $68.68M
Net Cash (Debt): $4.82M; $17.76M
Net Cash Per Share: $1.20; $0.80
Equity (Book Value): $3.91M; $53.89M
Book Value Per Share: $0.97; $1.50
Tangible Book Value: $3.91M; $27.13M

Cash flow (TTM)Industry

Operating Cash Flow: -$8.92M; -$12.38M

Dividends and yieldsIndustry

Earnings Yield: -380.1%; -21.8%

Scores and fair valueIndustry

Altman Z-Score: -21.34; 0.23

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	DRMA	S&P 500	Difference	DRMA per year	S&P 500 per year
1 month	-27.8%	-3.0%	−24.7 pts
3 months	-60.4%	-2.8%	−57.7 pts
Year to date	-73.2%	+11.5%	−84.7 pts
1 year	-80.2%	+13.5%	−93.7 pts
3 years	-99.4%	+77.7%	−177.1 pts	-81.6%	+21.1%
5 years	-100.0%	+72.6%	−172.6 pts	-86.1%	+11.5%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M DRMA shares were sold short on Oct 30, 2026, up 9.0% from the previous report, or 3.16% of the shares available to trade. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 39.8% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	84,233	+9.0%	406,501	1.0
Oct 15, 2026	77,279	-8.5%	15,414,814	1.0
Sep 30, 2026	84,484	-29.6%	23,429	3.6
Sep 15, 2026	120,024	-28.2%	37,704	3.2
Aug 31, 2026	167,251	-54.4%	142,173	1.2
Aug 14, 2026	366,825	+622.7%	4,126,993	1.0
Jul 31, 2026	50,755	-21.7%	48,748	1.0
Jul 15, 2026	64,856	-50.7%	88,114	1.0
Jun 30, 2026	131,494	+41.4%	106,781	1.2
Jun 15, 2026	92,975	-3.7%	59,670	1.6
May 29, 2026	96,498	-15.8%	47,583	2.0
May 15, 2026	114,588	-24.2%	52,304	2.2

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?